Mangrove Partners Immunovant, Inc. Transaction History

Mangrove Partners

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$3.38 - $5.65 $1.24 Million - $2.08 Million	-368,000 Closed	0 $0
Q1 2022 May 16, 2022	SELL	$5.06 - $8.77 $1.62 Million - $2.81 Million	-320,000 Reduced 46.51%	368,000 $2.03 Million
Q4 2021 Feb 14, 2022	BUY	$7.33 - $9.32 $1.38 Million - $1.75 Million	188,000 Added 37.6%	688,000 $5.86 Million
Q3 2021 Nov 15, 2021	BUY	$7.01 - $11.37 $102,570 - $166,365	14,632 Added 3.01%	500,000 $4.35 Million
Q2 2021 Aug 16, 2021	BUY	$9.4 - $16.85 $4.56 Million - $8.18 Million	485,368 New	485,368 $5.13 Million
Q2 2021 Aug 16, 2021	SELL	$9.4 - $16.85 $4.56 Million - $8.18 Million	-485,368 Closed	0 $0
Q1 2021 May 17, 2021	BUY	$13.08 - $49.6 $6.35 Million - $24.1 Million	485,368 New	485,368 $7.79 Million
Q4 2020 Feb 16, 2021	SELL	$36.36 - $52.71 $8.37 Million - $12.1 Million	-230,307 Closed	0 $0
Q3 2020 Nov 16, 2020	BUY	$22.61 - $38.9 $2.26 Million - $3.89 Million	100,000 Added 76.74%	230,307 $8.11 Million
Q2 2020 Aug 14, 2020	SELL	$13.87 - $28.44 $6.13 Million - $12.6 Million	-441,635 Reduced 77.22%	130,307 $3.17 Million
Q1 2020 May 15, 2020	BUY	$8.36 - $17.13 $3.95 Million - $8.08 Million	471,942 Added 471.94%	571,942 $8.9 Million
Q4 2019 Feb 14, 2020	BUY	$10.02 - $16.4 $1 Million - $1.64 Million	100,000 New	100,000 $1.59 Million

211

66.9M

2.3M

631K

Ticker IMVT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 129,077,000
Market Cap $3.55B
Description
Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of mya...

Get notified when there are updates to the investment portfolio of Mangrove Partners, based on Form 13F filings with the SEC.

Stay updated on Mangrove Partners with notifications on news.